Ngoc-Quynh Chu1, Rong Liu1, Aaron Colby2, Claire de Forcrand1, Robert F Padera3, Mark W Grinstaff2, Yolonda L Colson4. 1. Division of Thoracic Surgery, Department of Surgery, Massachusetts General Hospital, Boston, Mass. 2. Departments of Biomedical Engineering and Chemistry, Boston University, Boston, Mass. 3. Department of Pathology, Brigham and Women's Hospital, Boston, Mass. 4. Division of Thoracic Surgery, Department of Surgery, Massachusetts General Hospital, Boston, Mass. Electronic address: ycolson@partners.org.
Abstract
OBJECTIVE: Malignant pleural mesothelioma is a lethal malignancy with poor survival and high local recurrence rates despite multimodal therapy with cytoreduction and chemoradiation. We evaluated the antitumor efficacy of a paclitaxel-loaded pH-responsive expansile nanoparticle (PTX-eNP) in 2 clinically relevant murine xenograft models of malignant pleural mesothelioma. METHODS: Luciferase-transfected MSTO-211H human mesothelioma cells were injected into the thoracic cavity of immunodeficient Nu/J mice. Tumor burden was monitored by bioluminescent imaging. Animals were randomized into 2 models of disease treatment chemotherapy with PTX-eNPs alone delivered locally for early limited disease or cytoreductive surgery plus local PTX-eNP chemotherapy for advanced disease. Within each disease model, anti-tumor efficacy of PTX-eNP was compared against standard formulation paclitaxel and drug-empty nanoparticles. Influence on survival was calculated. Fluorescently labeled PTX-eNPs and immunohistochemistry evaluated in vivo drug localization to tumor. RESULTS: Intrathoracic injection of MSTO-211H resulted in large tumor deposits distributed within the pleural space of the murine thoracic cavity. Local multidose treatment with PTX-eNPs alone in limited stage disease more than doubled survival compared with drug-empty nanoparticles (P ≤ .0001) and standard formulation paclitaxel (P = .0004). In the model of advanced disease, local multidose treatment with PTX-eNPs following cytoreductive surgery also prolonged survival by 126% and 69.4% compared with drug-empty nanoparticles (P = .0018) and standard formulation paclitaxel (P = .03457), respectively. Immunohistology demonstrated PTX-eNP accumulation within tumor cells in vitro and in vivo. CONCLUSIONS: Local delivery of paclitaxel via eNPs confers prolonged survival in a murine model of malignant pleural mesothelioma as single modality treatment for limited disease and in combination with cytoreductive surgery for advanced disease.
OBJECTIVE:Malignant pleural mesothelioma is a lethal malignancy with poor survival and high local recurrence rates despite multimodal therapy with cytoreduction and chemoradiation. We evaluated the antitumor efficacy of a paclitaxel-loaded pH-responsive expansile nanoparticle (PTX-eNP) in 2 clinically relevant murine xenograft models of malignant pleural mesothelioma. METHODS: Luciferase-transfected MSTO-211Hhumanmesothelioma cells were injected into the thoracic cavity of immunodeficient Nu/J mice. Tumor burden was monitored by bioluminescent imaging. Animals were randomized into 2 models of disease treatment chemotherapy with PTX-eNPs alone delivered locally for early limited disease or cytoreductive surgery plus local PTX-eNP chemotherapy for advanced disease. Within each disease model, anti-tumor efficacy of PTX-eNP was compared against standard formulation paclitaxel and drug-empty nanoparticles. Influence on survival was calculated. Fluorescently labeled PTX-eNPs and immunohistochemistry evaluated in vivo drug localization to tumor. RESULTS: Intrathoracic injection of MSTO-211H resulted in large tumor deposits distributed within the pleural space of the murine thoracic cavity. Local multidose treatment with PTX-eNPs alone in limited stage disease more than doubled survival compared with drug-empty nanoparticles (P ≤ .0001) and standard formulation paclitaxel (P = .0004). In the model of advanced disease, local multidose treatment with PTX-eNPs following cytoreductive surgery also prolonged survival by 126% and 69.4% compared with drug-empty nanoparticles (P = .0018) and standard formulation paclitaxel (P = .03457), respectively. Immunohistology demonstrated PTX-eNP accumulation within tumor cells in vitro and in vivo. CONCLUSIONS: Local delivery of paclitaxel via eNPs confers prolonged survival in a murine model of malignant pleural mesothelioma as single modality treatment for limited disease and in combination with cytoreductive surgery for advanced disease.
Authors: Yolonda L Colson; Rong Liu; Emily B Southard; Morgan D Schulz; Jacqueline E Wade; Aaron P Griset; Kimberly Ann V Zubris; Robert F Padera; Mark W Grinstaff Journal: Biomaterials Date: 2010-11-01 Impact factor: 12.479
Authors: V W Rusch; D Niedzwiecki; Y Tao; C Menendez-Botet; A Dnistrian; D Kelsen; L Saltz; M Markman Journal: J Clin Oncol Date: 1992-06 Impact factor: 44.544
Authors: Morgan D Schulz; Kimberly Ann V Zubris; Jacqueline E Wade; Robert F Padera; Xiaoyin Xu; Mark W Grinstaff; Yolonda L Colson Journal: Ann Thorac Surg Date: 2011-10-01 Impact factor: 4.330
Authors: David A Mahvi; Rong Liu; Mark W Grinstaff; Yolonda L Colson; Chandrajit P Raut Journal: CA Cancer J Clin Date: 2018-10-17 Impact factor: 508.702
Authors: Balazs Hegedus; Balazs Dome; Viktoria Laszlo; Zsuzsanna Valko; Ildiko Kovacs; Judit Ozsvar; Mir Alireza Hoda; Thomas Klikovits; Dora Lakatos; Andras Czirok; Tamas Garay; Alexander Stiglbauer; Thomas H Helbich; Marion Gröger; Jozsef Tovari; Walter Klepetko; Christine Pirker; Michael Grusch; Walter Berger; Frank Hilberg Journal: Clin Cancer Res Date: 2018-05-03 Impact factor: 12.531
Authors: Kimberly Ann V Zubris; Rong Liu; Aaron Colby; Morgan D Schulz; Yolonda L Colson; Mark W Grinstaff Journal: Biomacromolecules Date: 2013-05-09 Impact factor: 6.988